Key Trends and Insights into the Preeclampsia Drugs Market: Growth Rate and Opportunities to 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the preeclampsia drugs market grown over the years?
The preeclampsia drugs market has grown significantly, with its size expected to increase from $1.25 billion in 2024 to $1.38 billion in 2025, registering a CAGR of 10.6%. Key factors driving past growth include heightened maternal health awareness, advancements in research and development, neonatal health concerns, and improvements in early detection.
What Is the forecasted market size and growth rate for the preeclampsia drugs market?
The preeclampsia drugs market is projected to expand rapidly, reaching $2.12 billion in 2029 with an 11.3% CAGR. Growth is fueled by advancements in personalized medicine, non-invasive diagnostics, targeted therapies, and health equity initiatives. Emerging trends include preventive strategies, patient-centered care, continuous monitoring, and regulatory developments.
Get your preeclampsia drugs market report here!
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
What are the major factors driving growth in the preeclampsia drugs market?
The upward trend in diabetes among expectant mothers is predicted to fuel the expansion of the preeclampsia drug market. A metabolic disorder, diabetes, is a long-term illness characterized by elevated levels of blood glucose or sugar. Preeclampsia is a harmful pregnancy condition with increased blood pressure and organ damage. Metformin, a preeclampsia medicine, is commonly used in pregnant women with early onset preeclampsia. For instance, the National Library of Medicine, a US-based biomedical library and center of biomedical informatics, reported in December 2022 that the total incidence of gestational diabetes mellitus (GDM) was 20,865 cases, representing a 6.56% increase in 2022. Hence, the increasing incidence of diabetes among pregnant women will bolster the preeclampsia drug market. The swelling prevalence of lifestyle-related illnesses is anticipated to drive the growth of the preeclampsia drugs market. Lifestyle diseases, also known as non-communicable diseases (NCDs), are principally caused by unhealthy lifestyle choices and behaviors. These diseases, which include hypertension, obesity, and diabetes, are risk factors for preeclampsia and thus treated with preeclampsia drugs. According to the World Health Organization, a Switzerland-based specialized agency of the United Nations, in September 2022, there were 41 million deaths, which accounts for 74% of the total fatalities caused by NCDs or chronic diseases every year worldwide. These figures included 17.9 million deaths from cardiovascular illnesses, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Thus, the escalating prevalence of lifestyle diseases drives the expansion of the preeclampsia drugs market.
What key areas define the segmentation of the global preeclampsia drugs Market?
The preeclampsia drugs market covered in this report is segmented –
1) By Type: Mild Preeclampsia, Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp
What are the top market players propelling the growth of the preeclampsia drugs industry?
Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.
What are the key trends shaping the future of the preeclampsia drugs market?
In an effort to strengthen their hold on the preeclampsia medicine market, leading companies are concentrating on creating innovative drug solutions. To illustrate, Comanche Biopharma Corp., a biopharmaceutical company based in the US, announced in March 2023 that the Food and Drug Administration (FDA) gave approval to a new investigational drug (IND) application for CBP-4888. This is Comanche’s unique siRNA treatment for preeclampsia. Administered subcutaneously, CBP-4888 is a siRNA therapy that mitigates the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The main reason for preeclampsia is the excess production of the protein sFLT1 in the placenta that then makes its way into the mother’s circulation. Symptoms of preeclampsia such as elevated blood pressure and organ damage can be alleviated by CBP-4888, potentially enabling a safe prolongation of pregnancy.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13025
What regions are dominating the preeclampsia drugs market growth?
North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Female Fertility And Pregnancy Rapid Test Global Market Report 2024
Fertility Treatments Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report
Hormonal Contraceptives Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
